- BIOSTEP(TM) Collagen Matrix Dressing, and
- BIOSTEP(TM) Ag Collagen Matrix Dressing with Silver.
The products are advanced wound care dressings that create a moist wound healing environment, deactivate harmful wound proteases and promote tissue growth in chronic wounds, which affect an increasingly large number of patients and have a serious impact on their quality of life.
The products will be marketed by Smith & Nephew Inc. under the terms of an exclusive worldwide sales, marketing and distribution agreement announced last year.
"We are extremely pleased to receive license approvals for these products" said Dr. Frank DiCosmo, President and CEO of Covalon. "Clinicians participating at a clinical in-market study indicated that these new collagen dressings facilitate granulation and epidermal migration as the majority of patients experienced a reduction in wound areas and an increase in the percentage of epithelial tissue over time. In the case of BIOSTEP(TM) Ag, participating clinicians indicated that absorption of silver by the cells appears to improve the local microenvironment to promote the healing process". BIOSTEP(TM) and BIOSTEP(TM)Ag are manufactured in the U.S.A. by Covalon Technologies Ltd., exclusively for Smith & Nephew; (TM)Trademark of Smith & Nephew.
"Covalon's talented research and development staff is actively working on broadening our proprietary collagen-based platform in order to address other exciting medical applications in the near future", said Dr. DiCosmo.
About Covalon Technologies Ltd.:
Covalon Technologies Ltd. researches and develops advanced medical products initially targeted at wound care and surgical applications and coatings. Covalon's patented technology utilizes advanced therapeutic biomaterials polymer chemistry and surface coatings to create a range of time-release drug delivery platforms that are applied to many medical devices to treat many critical conditions. A variety of applications for these technologies have been identified and specific products have been developed. The products offer features and benefits providing solutions to many of the problems caused by current devices and their material properties which are used by most medical device manufacturers and suppliers. The problems include infection, poor biocompatibility, and microbial attachment.
Additional information can be found at www.covalon.com.
This document contains forward-looking statements. These statements relate to future events or future performance. In some cases, forward-looking statements can be identified by terminology such as "may", "will", "should", "expect", "plan", "anticipate", "believe", "estimate", "predict", "potential", "continue" or the negative of any of these terms or comparable terminology. Such statements reflect the current views of management of the Company with respect to future events. Actual events or results may differ materially. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments.
ISO 13485:2003 CERTIFIED
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. The TSX Venture Exchange has neither approved nor disapproved of the contents of this release.
Contact: Contacts: Covalon Technologies Ltd. Frank DiCosmo, Ph.D. President & CEO (905) 568-8400
Covalon Technologies Ltd. Francis K. Lindayen, C.A. CFO (905) 568-8400 Website: http://www.covalon.com
Source: Covalon Technologies Ltd.
